Patents by Inventor Paul Beswick

Paul Beswick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11453702
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.
    Type: Grant
    Filed: September 30, 2021
    Date of Patent: September 27, 2022
    Assignee: BICYCLETX LIMITED
    Inventors: Paul Beswick, Liuhong Chen, Gemma Mudd, Peter Park, Katerine Van Rietschoten, Michael Rigby
  • Publication number: 20220281918
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of penicillin-binding proteins (PBPs). The invention also includes pharmaceutical compositions comprising said peptide ligands and to the use of said peptide ligands in suppressing or treating a disease or disorder mediated by bacterial infection or for providing prophylaxis to a subject at risk of infection.
    Type: Application
    Filed: August 28, 2020
    Publication date: September 8, 2022
    Inventors: Katerine VAN RIETSCHOTEN, Paul BESWICK, Mike DAWSON, Matthew BALMFORTH, Michael SKYNNER, Liuhong CHEN
  • Patent number: 11396530
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: October 28, 2020
    Date of Patent: July 26, 2022
    Assignee: BICYCLETX LIMITED
    Inventors: Paul Beswick, Gemma Elizabeth Mudd, Kevin McDonnell, Gabriela Ivanova-Berndt, Katerine Van Rietschoten, David Witty, Michael Skynner
  • Patent number: 11298345
    Abstract: The invention provides compounds of the formula (I): (I) wherein A1, A2, R2, R4, B1, B2, X, X1, n, a and b are as defined are defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: April 12, 2022
    Assignee: University College Cardiff Consultants Limited
    Inventors: Simon Ward, Paul Beswick, Lewis Pennicott, Tristan Reuillon, Irina Chuckowree, Carolina Villalonga-Barber, Roderick Alan Porter
  • Publication number: 20220089643
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.
    Type: Application
    Filed: September 30, 2021
    Publication date: March 24, 2022
    Inventors: Paul BESWICK, Liuhong CHEN, Gemma MUDD, Peter PARK, Katerine VAN RIETSCHOTEN, Michael RIGBY
  • Patent number: 11186567
    Abstract: The invention provides compounds of the formula (I): wherein R1 and R2 are defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: November 30, 2021
    Assignee: University College Cardiff Consultants Limited
    Inventors: Simon Ward, Paul Beswick, Lewis Pennicott, Tristan Reuillon
  • Patent number: 11180531
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: November 23, 2021
    Assignee: BicycleTx Limited
    Inventors: Paul Beswick, Liuhong Chen, Gemma Mudd, Peter Park, Katerine Van Rietschoten, Michael Rigby
  • Publication number: 20210269480
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4.The invention also includes drug conjugates comprising said peptides,conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.
    Type: Application
    Filed: June 21, 2019
    Publication date: September 2, 2021
    Inventors: Paul BESWICK, Liuhong CHEN, Gemma Elizabeth MUDD, Peter PARK, Katerine VAN RIETSCHOTEN, Michael RIGBY
  • Publication number: 20210147484
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: October 28, 2020
    Publication date: May 20, 2021
    Inventors: Paul BESWICK, Gemma Elizabeth Mudd, Kevin McDonnell, Gabriela Ivanova-Berndt, Katerine Van Rietschoten, David Witty, Michael Skynner
  • Publication number: 20210139463
    Abstract: The invention provides compounds of the formula (I): wherein R1 and R2 are defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia.
    Type: Application
    Filed: February 9, 2018
    Publication date: May 13, 2021
    Inventors: Simon Ward, Paul Beswick, Lewis Pennicott, Tristan Reuillon
  • Publication number: 20210113539
    Abstract: The invention provides compounds of the formula (I): (I) wherein A1, A2, R2, R4, B1, B2, X, X1, n, a and b are as defined are defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia.
    Type: Application
    Filed: March 1, 2019
    Publication date: April 22, 2021
    Inventors: Simon WARD, Paul BESWICK, Lewis PENNICOTT, Tristan REUILLON, Irina CHUCKOWREE, Carolina VILLALONGA-BARBER, Roderick Alan PORTER
  • Patent number: 10919937
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: October 23, 2019
    Date of Patent: February 16, 2021
    Assignee: BicycleTx Limited
    Inventors: Paul Beswick, Gemma Elizabeth Mudd, Kevin McDonnell, Gabriela Ivanova-Berndt, Katerine Van Rietschoten, David Witty, Michael Skynner
  • Publication number: 20200131228
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: October 23, 2019
    Publication date: April 30, 2020
    Inventors: Paul Beswick, Gemma Elizabeth Mudd, Kevin McDonnell, Gabriela Ivanova-Berndt, Katerine Van Rietschoten, David Witty, Michael Skynner
  • Publication number: 20190389906
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.
    Type: Application
    Filed: June 20, 2019
    Publication date: December 26, 2019
    Inventors: Paul Beswick, Liuhong Chen, Gemma Mudd, Peter Park, Katerine Van Rietschoten, Michael Rigby
  • Patent number: 9750719
    Abstract: The present invention relates to novel tetrazole compounds; to processes for their preparation; to pharmaceutical compositions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: September 5, 2017
    Assignee: CONVERGENCE PHARMACEUTICALS LIMITED
    Inventors: Paul Beswick, Robert James Gleave, Shuji Hachisu, Sadie Vile, Nicolas Bertheleme, Simon E. Ward
  • Publication number: 20160015687
    Abstract: The present invention relates to novel tetrazole compounds; to processes for their preparation; to pharmaceutical compositions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial.
    Type: Application
    Filed: July 17, 2015
    Publication date: January 21, 2016
    Applicant: CONVERGENCE PHARMACEUTICALS LIMITED
    Inventors: Paul BESWICK, Robert James GLEAVE, Shuji HACHISU, Sadie VILE, Nicolas BERTHELEME, Simon E. WARD
  • Patent number: 9115132
    Abstract: The present invention relates to novel tetrazole compounds of Formula (I) wherein A is (II) or (III); to processes for their preparation; to pharmaceutical compositions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: August 25, 2015
    Assignee: Convergence Pharmaceuticals Limited
    Inventors: Paul Beswick, Robert James Gleave, Shuji Hachisu, Sadie Vile, Nicholas Bertheleme, Simon E. Ward
  • Publication number: 20130210796
    Abstract: The present invention relates to novel tetrazole compounds; to processes for their preparation; to pharmaceutical compositions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial.
    Type: Application
    Filed: July 8, 2011
    Publication date: August 15, 2013
    Inventors: Paul Beswick, Robert James Gleave, Shuji Hachisu, Sadie Vile, Nicholas Bertheleme, Simon E. Ward
  • Patent number: 7446117
    Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof are potent and selective inhibitors of COX-2 and are of use in the treatment of the pain, fever and inflammation of a variety of conditions and diseases.
    Type: Grant
    Filed: September 12, 2003
    Date of Patent: November 4, 2008
    Assignee: Glaxo Group Limited
    Inventors: Paul Beswick, Neil Pegg, Martin Swarbrick, John Skidmore, Sandeep Modi
  • Publication number: 20060270880
    Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof are potent and selective inhibitors of COX-2 and are of use in the treatment of the pain, fever and inflammation of a variety of conditions and diseases.
    Type: Application
    Filed: August 11, 2004
    Publication date: November 30, 2006
    Inventors: Paul Beswick, Robert Gleave, Martin Swarbrick